Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Fam-trastuzumab deruxtecan-NXKI in HER2-Expressing Endometrial Carcinoma: NCT07022483 Clinical Landscape Report 2026
15 October 2026
NCT07022483 clinical landscape for HER2-Expressing Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Lenalidomide in Multiple Myeloma: NCT07025005 Clinical Landscape Report 2026
15 October 2026
NCT07025005 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Miristen in Recurrent Acute Leukemia: NCT07025564 Clinical Landscape Report 2026
15 October 2026
NCT07025564 clinical landscape for Recurrent Acute Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Doxorubicin Hydrochloride in Metastatic Soft Tissue Sarcoma: NCT07027423 Clinical Landscape Report 2026
15 October 2026
NCT07027423 clinical landscape for Metastatic Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Belzutifan in Metastatic Clear Cell Renal Cell Carcinoma: NCT07023432 Clinical Landscape Report 2026
15 October 2026
NCT07023432 clinical landscape for Metastatic Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT07023588 Clinical Landscape Report 2026
15 October 2026
NCT07023588 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT07028086 Clinical Landscape Report 2026
15 October 2026
NCT07028086 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD8-IL21(Asher Biotherapeutics) in Locally Advanced Malignant Solid Neoplasm: NCT07027488 Clinical Landscape Report 2026
15 October 2026
NCT07027488 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Fludarabine Phosphate in Acute Myeloid Leukemia: NCT07025824 Clinical Landscape Report 2026
15 October 2026
NCT07025824 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Universal donor derived CD33 CAR-NK(Nationwide Children's Hospital) in Refractory acute myeloid leukemia: NCT07026942 Clinical Landscape Report 2026
15 October 2026
NCT07026942 clinical landscape for Refractory acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Nivolumab in Metastatic Renal Cell Carcinoma: NCT07028125 Clinical Landscape Report 2026
15 October 2026
NCT07028125 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Extramedullary Disease in Multiple Myeloma: NCT07029776 Clinical Landscape Report 2026
15 October 2026
NCT07029776 clinical landscape for Extramedullary Disease in Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development…